Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.

Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group.Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10.PMID: 36099927

 

Melanomversorgung während eines Jahres Pandemie in Berlin: abnehmende Terminstornierungen trotz zunehmender Besorgnis über COVID-19.

Micek A, Diehl K, Teuscher M, Schaarschmidt ML, Sasama B, Ohletz J, Burbach G, Kiecker F, Hillen U, Harth W, Peitsch WK.J Dtsch Dermatol Ges. 2022 Jul;20(7):962-979. doi: 10.1111/ddg.14799_g.PMID: 35881087

 

Melanoma care during one year pandemic in Berlin: decreasing appointment cancellations despite increasing COVID-19 concern.

Micek A, Diehl K, Teuscher M, Schaarschmidt ML, Sasama B, Ohletz J, Burbach G, Kiecker F, Hillen U, Harth W, Peitsch WK.J Dtsch Dermatol Ges. 2022 Jul;20(7):962-978. doi: 10.1111/ddg.14799. Epub 2022 Jun 6.PMID: 35665996

 

First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.

D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P.J Immunother Cancer. 2021 Jul;9(7):e002646. doi: 10.1136/jitc-2021-002646.PMID: 34301810

 

Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases.

Zaremba A, Philip M, Hassel JC, Glutsch V, Fiocco Z, Loquai C, Rafei-Shamsabadi D, Gutzmer R, Utikal J, Haferkamp S, Reinhardt L, Kähler KC, Weishaupt C, Moreira A, Thoms KM, Wilhelm T, Pföhler C, Roesch A, Ugurel S, Zimmer L, Stadtler N, Sucker A, Kiecker F, Heinzerling L, Meier F, Meiss F, Schlaak M, Schilling B, Horn S, Schadendorf D, Livingstone E.Eur J Cancer. 2021 Jul;152:139-154. doi: 10.1016/j.ejca.2021.04.032. Epub 2021 Jun 5.PMID: 34102453

 

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.

Stege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, Becker JC, Meissner M, Kleeman J, Pföhler C, Hassel J, Grabbe S, Loquai C.Cancer Immunol Immunother. 2021 Nov;70(11):3313-3322. doi: 10.1007/s00262-021-02925-4. Epub 2021 Apr 18.PMID: 33870464

 

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group.Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12.PMID: 33857414

 

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group.Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12.PMID: 33857412

 

Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.

Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, Hassel JC, Weishaupt C, Eigentler T, Schilling B, Schummer P, Sirokay J, Kiecker F, Owen CN, Fleischer MI, Cann C, Kähler KC, Mohr P, Bluhm L, Niebel D, Thoms KM, Goldinger SM, Reinhardt L, Meier F, Berking C, Reinhard R, Susok L, Ascierto PA, Drexler K, Pföhler C, Tietze J, Heinzerling L, Livingstone E, Ugurel S, Long GV, Stang A, Schadendorf D, Zimmer L.Eur J Cancer. 2021 May;148:61-75. doi: 10.1016/j.ejca.2021.01.034. Epub 2021 Mar 15.PMID: 33735811

 

Patientenpräferenzen für die Therapie fortgeschrittener Melanome: Einfluss von Komorbidität.

Weilandt J, Diehl K, Schaarschmidt ML, Kiecker F, Sasama B, Pronk M, Ohletz J, Könnecke A, Müller V, Utikal J, Hillen U, Harth W, Peitsch WK.J Dtsch Dermatol Ges. 2021 Jan;19(1):58-72. doi: 10.1111/ddg.14293_g.PMID: 33491889

 

Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.

Gambichler T, Tsagoudis K, Kiecker F, Reinhold U, Stockfleth E, Hamscho R, Egberts F, Hauschild A, Amaral T, Garbe C.Eur J Cancer. 2021 Jan;143:11-18. doi: 10.1016/j.ejca.2020.10.016. Epub 2020 Dec 2.PMID: 33278769

 

Patient preferences for treatment of advanced melanoma: impact of comorbidities.

Weilandt J, Diehl K, Schaarschmidt ML, Kiecker F, Sasama B, Pronk M, Ohletz J, Könnecke A, Müller V, Utikal J, Hillen U, Harth W, Peitsch WK.J Dtsch Dermatol Ges. 2021 Jan;19(1):58-70. doi: 10.1111/ddg.14293. Epub 2020 Oct 4.PMID: 33015933

 

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP.Future Oncol. 2020 Sep;16(27):2089-2099. doi: 10.2217/fon-2020-0426. Epub 2020 Sep 17.PMID: 32938212

 

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.Nat Med. 2020 Jul;26(7):1147. doi: 10.1038/s41591-020-0975-4.PMID: 32561875

 

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.

Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer.J Clin Oncol. 2020 Aug 1;38(22):2543-2551. doi: 10.1200/JCO.19.03034. Epub 2020 Jun 12.PMID: 32530760

 

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.

Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L; *German Dermatological Cooperative Oncology Group.J Immunother Cancer. 2020 Mar;8(1):e000333. doi: 10.1136/jitc-2019-000333.PMID: 32221017

 

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS.Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.PMID: 31871622

 

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB.Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.PMID: 31864178

​

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.Nat Med. 2020 Jun 19. doi: 10.1038/s41591-020-0975-4.

 

Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.

Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM; German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer.J Clin Oncol. 2020 Jun 12:JCO1903034. doi: 10.1200/JCO.19.03034. Online ahead of print.PMID: 32530760

 

Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.

Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, Gutzmer R, Haferkamp S, Uttikal J, Berking C, Rafei-Shamsabadi D, Reinhardt L, Meier F, Karoglan A, Posch C, Gambichler T, Pfoehler C, Thoms K, Tietze J, Debus D, Herbst R, Emmert S, Loquai C, Hassel JC, Meiss F, Tueting T, Heinrich V, Eigentler T, Garbe C, Zimmer L; *German Dermatological Cooperative Oncology Group.J Immunother Cancer. 2020 Mar;8(1):e000333. doi: 10.1136/jitc-2019-000333.PMID: 32221017

 

Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.

Mohr P, Kiecker F, Soriano V, Dereure O, Mujika K, Saiag P, Utikal J, Koneru R, Robert C, Cuadros F, Chacón M, Villarroel RU, Najjar YG, Kottschade L, Couselo EM, Koruth R, Guérin A, Burne R, Ionescu-Ittu R, Perrinjaquet M, Zager JS.Melanoma Manag. 2019 Oct 4;6(4):MMT33. doi: 10.2217/mmt-2019-0015.PMID: 31871622

 

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A Jr, Gasal E, Mookerjee B, Chapman PB.Eur J Cancer. 2020 Jan;125:114-120. doi: 10.1016/j.ejca.2019.10.033.PMID: 31864178

 

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.Version 2. Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5. Epub 2019 Dec 2.PMID: 31792460

 

Neuronal autoantibodies associated with cognitive impairment in melanoma patients.

Bartels F, Strönisch T, Farmer K, Rentzsch K, Kiecker F, Finke C.Ann Oncol. 2019 May 1;30(5):823-829. doi: 10.1093/annonc/mdz083.PMID: 30840061

 

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.PMID: 30739835

 

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.PMID: 30690294

 

Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.

Yan BY, Garcet S, Gulati N, Kiecker F, Fuentes-Duculan J, Gilleaudeau P, Sullivan-Whalen M, Shemer A, Mitsui H, Krueger JG.Exp Dermatol. 2019 Jan;28(1):35-44. doi: 10.1111/exd.13805. Epub 2018 Dec 21.PMID: 30326165

 

Crucial role of reactive oxygen species (ROS) for the proapoptotic effects of indirubin derivative DKP-073 in melanoma cells.

Zhivkova V, Kiecker F, Langer P, Eberle J.Mol Carcinog. 2019 Feb;58(2):258-269. doi: 10.1002/mc.22924. Epub 2018 Nov 2.PMID: 30320471

 

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL.JAMA Oncol. 2018 Sep 1;4(9):e180077. doi: 10.1001/jamaoncol.2018.0077. Epub 2018 Sep 13.PMID: 29566106

 

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.PMID: 29438368

 

Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.

Becker JC, Lorenz E, Ugurel S, Eigentler TK, Kiecker F, Pföhler C, Kellner I, Meier F, Kähler K, Mohr P, Berking C, Haas G, Helwig C, Oksen D, Schadendorf D, Mahnke L, Bharmal M.Oncotarget. 2017 Jul 13;8(45):79731-79741. doi: 10.18632/oncotarget.19218. eCollection 2017 Oct 3.PMID: 29108353

 

Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients.

Heppt MV, Schlaak M, Eigentler TK, Kähler KC, Kiecker F, Loquai C, Meier F, Tomsitz D, Brenner N, Niesert AC, Thonke R, Hauschild A, Berking C.Ann Oncol. 2017 Dec 1;28(12):3104-3106. doi: 10.1093/annonc/mdx538.PMID: 28950303

 

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20.PMID: 28735071

 

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C.Eur J Cancer. 2017 Sep;82:56-65. doi: 10.1016/j.ejca.2017.05.038. Epub 2017 Jun 22.PMID: 28648699

 

Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.

Bauer D, Werth F, Nguyen HA, Kiecker F, Eberle J.Cell Death Dis. 2017 Feb 2;8(2):e2594. doi: 10.1038/cddis.2017.6.PMID: 28151482

 

A systematic review of the role of interleukin-17 and the interleukin-20 family in inflammatory allergic skin diseases.

Hofmann MA, Kiecker F, Zuberbier T.Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):451-7. doi: 10.1097/ACI.0000000000000310.PMID: 27490126

 

Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria.

Mitsui H, Kiecker F, Shemer A, Cannizzaro MV, Wang CQF, Gulati N, Ohmatsu H, Shah KR, Gilleaudeau P, Sullivan-Whalen M, Cueto I, McNutt NS, Suárez-Fariñas M, Krueger JG.J Invest Dermatol. 2016 Oct;136(10):2030-2040. doi: 10.1016/j.jid.2015.11.035. Epub 2016 Jul 1.PMID: 27377700

 

Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.

Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C; Dermatologic Cooperative Oncology Group (DeCOG).Ann Oncol. 2016 Aug;27(8):1625-32. doi: 10.1093/annonc/mdw225. Epub 2016 Jun 10.PMID: 27287206

 

Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.

Zimmer L, Eigentler TK, Kiecker F, Simon J, Utikal J, Mohr P, Berking C, Kämpgen E, Dippel E, Stadler R, Hauschild A, Fluck M, Terheyden P, Rompel R, Loquai C, Assi Z, Garbe C, Schadendorf D.J Transl Med. 2015 Nov 6;13:351. doi: 10.1186/s12967-015-0716-5.PMID: 26541511

 

Dendritic cells are contained within melanocytic nevus nests in vivo and can alter gene expression of epidermal melanocytes in vitro.

Gulati N, Mitsui H, Fuentes-Duculan J, Gonzalez J, Wang CQ, Shah KR, Gilleaudeau P, Sullivan-Whalen M, Kiecker F, McNutt NS, Suárez-Fariñas M, Krueger JG.Pigment Cell Melanoma Res. 2015 Jan;28(1):110-3. doi: 10.1111/pcmr.12324. Epub 2014 Nov 3.PMID: 25308477

 

Regional nodal relapse in surgically staged Merkel cell carcinoma.

Hoeller U, Mueller T, Schubert T, Budach V, Ghadjar P, Brenner W, Kiecker F, Schicke B, Haase O.Strahlenther Onkol. 2015 Jan;191(1):51-8. doi: 10.1007/s00066-014-0756-4. Epub 2014 Oct 8.PMID: 25293726

 

Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma.

Hofmann MA, Kiecker F, Küchler I, Kors C, Trefzer U.J Cancer Res Clin Oncol. 2011 Mar;137(3):455-62. doi: 10.1007/s00432-010-0900-1. Epub 2010 May 9.PMID: 20454974

 

Hypertrichosis in three patients treated with interferon-alpha2.

Kiecker F, Hofmann MA, Trefzer U.Clin Exp Dermatol. 2009 Oct;34(7):e414-5. doi: 10.1111/j.1365-2230.2009.03393.x. Epub 2009 Jul 29.PMID: 19663862

 

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.

Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D.Melanoma Res. 2008 Aug;18(4):274-8. doi: 10.1097/CMR.0b013e328307c248.PMID: 18626312

 

Amelanotic metastasis of melanoma mimicking ovarian cancer: a case report and review of the literature.

Pietzner K, Noske A, Cho CH, Kiecker F, Sehouli J.Anticancer Res. 2008 Jan-Feb;28(1B):563-6.PMID: 18383903

 

High-dose platinum combination therapy in pretreated patients with disseminated melanoma.

Hofmann MA, Gabriel V, Milling A, Kiecker F, Sterry W, Trefzer U.Chemotherapy. 2007;53(6):422-8. doi: 10.1159/000110007. Epub 2007 Oct 19.PMID: 17952002 Clinical Trial.

 

Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women?

Hofmann MA, Coll SH, Küchler I, Kiecker F, Wurm R, Sterry W, Trefzer U.Dermatology. 2007;215(1):10-6. doi: 10.1159/000102028.PMID: 17587834

 

Large primary meningeal melanoma in an adult patient with neurocutaneous melanosis.

Kiecker F, Hofmann MA, Audring H, Brenner A, Labitzke C, Sterry W, Trefzer U.Clin Neurol Neurosurg. 2007 Jun;109(5):448-51. doi: 10.1016/j.clineuro.2007.02.004. Epub 2007 Mar 26.PMID: 17382464

 

Vitiligo-like depigmentation as a presenting sign of metastatic melanoma.

Kiecker F, Hofmann M, Sterry W, Trefzer U.J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1135-7. doi: 10.1111/j.1468-3083.2006.01628.x.PMID: 16987274 No abstract available.

 

The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma.

Trefzer U, Chen Y, Herberth G, Hofmann MA, Kiecker F, Guo Y, Sterry W.BMC Cancer. 2006 Jan 11;6:8. doi: 10.1186/1471-2407-6-8.PMID: 16405722

 

Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.

Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, Baumann G, Trefzer U.Cardiovasc Ultrasound. 2005 Sep 2;3:26. doi: 10.1186/1476-7120-3-26.PMID: 16138923

 

Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.

Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, Trefzer U.J Neurooncol. 2006 Jan;76(1):59-64. doi: 10.1007/s11060-005-2914-0.PMID: 16132502

 

Diffuse melanosis cutis in disseminated malignant melanoma.

Hofmann M, Kiecker F, Audring H, Grefer K, Sterry W, Trefzer U.Dermatology. 2004;209(4):350-2. doi: 10.1159/000080871.PMID: 15539910

 

Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose?

Kiecker F, Streitz M, Ay B, Cherepnev G, Volk HD, Volkmer-Engert R, Kern F.Hum Immunol. 2004 May;65(5):523-36. doi: 10.1016/j.humimm.2004.02.017.PMID: 15172453

 

Mapping T cell epitopes by flow cytometry.

Hoffmeister B, Kiecker F, Tesfa L, Volk HD, Picker LJ, Kern F.Methods. 2003 Mar;29(3):270-81. doi: 10.1016/s1046-2023(02)00349-3.PMID: 12725792 Review.

 

Evaluation of the frequency of virus-specific CD8+ T cells by cytokine flow cytometry.

Hoffmeister B, Kiecker F, Surel I, Khatamzas E, Schuster V, Volk HD, Kern F.Methods Mol Biol. 2003;215:59-69. doi: 10.1385/1-59259-345-3:59.PMID: 12512291 No

 

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals.

Kern F, Bunde T, Faulhaber N, Kiecker F, Khatamzas E, Rudawski IM, Pruss A, Gratama JW, Volkmer-Engert R, Ewert R, Reinke P, Volk HD, Picker LJ.J Infect Dis. 2002 Jun 15;185(12):1709-16. doi: 10.1086/340637. Epub 2002 May 31.PMID: 12085315